DRMA — Dermata Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1853816 ·
Last close
$0.57
Market Cap
$2.81M
52W High
$4.66
52W Low
$0.57
ADV30
5,885,688
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 74,137 | 40,129 | -2,858,499 | -2,821,400 | 6,635,491 | 4,822,357 | 2,729,565 |
| Jun 2026 | 0 | — | -3,013,567 | -2,967,063 | 5,320,799 | 4,412,764 | 1,833,079 |
| Mar 2026 | 0 | — | -1,926,382 | -1,847,706 | 7,465,652 | 6,945,282 | 1,052,649 |
| Dec 2025 | 0 | — | -1,900,393 | -1,861,888 | 7,863,826 | 7,521,978 | 1,640,446 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,034,258
Investing CF
—
Financing CF
$6,076,759
CapEx
—
Dividends Paid
—
Buybacks
$-367
EPS Diluted TTM
$-4.53
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,048,665
Inventory
$149,734
Receivables
—
ST Investments
—
EBIT TTM
$-8,601,013
Pretax Income TTM
$-8,368,646
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$74,137
EBITDA
—
Free Cash Flow
$-5,651,833
Enterprise Value
$-1,759,712
Total Cash
$4,822,357
Total Debt
$0
Shares Out
4,930,207
Trailing EPS
$-4.39
Book Value
$0.79
ROE
-241.5%
ROA
-103.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,773,598 | -7,558,557 | 7,863,826 | 1,640,446 | 6,223,380 | -7,757,559 |
| Dec 2024 | 0 | -12,513,242 | -12,287,461 | 3,533,888 | 1,972,794 | 1,561,094 | -11,162,948 |
| Dec 2023 | 0 | -8,041,906 | -7,794,690 | 7,978,634 | 1,623,616 | 6,355,018 | -6,408,931 |
| Dec 2022 | 0 | -9,674,486 | -9,610,913 | 6,944,488 | 922,634 | 6,021,854 | -8,834,164 |
TTM Snapshot
Revenues TTM
$232,367
NetIncome TTM
$-8,368,646
OpCashFlow TTM
—
Assets (Latest)
$5,320,799
Forward EPS
$-3.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PPBT | PURPLE BIOTECH LTD. | $2.78M | $1.71 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $2.86M | $1.51 | — |
| GELS | Gelteq Ltd | $2.88M | $0.27 | — |
| MDCX | Medicus Pharma Ltd. | $2.89M | $1.52 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $2.94M | $1.95 | — |
News headlines (Yahoo Finance, 1h cache)
Dermata Announces U.S. Trademark Registration for TOME(R)
2026-11-18 13:35 · Yahoo
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
2026-11-17 13:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
2026-11-10 21:05 · Yahoo
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
2026-11-05 13:30 · Yahoo
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
2026-10-29 20:05 · Yahoo
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
2026-10-15 12:05 · Yahoo
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Labor
2026-08-31 09:05 · Yahoo
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
2026-08-25 12:30 · Yahoo
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
2026-08-21 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
2026-08-11 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.